Today on #RareDiseaseDay, we celebrate a recent significant milestone: the first participant to receive HMB-002, our investigational treatment for Von Willebrand Disease. Their courage to step forward and get involved advances research towards better treatment options and also helps shape the future for the next generation. We are deeply grateful to the participants, investigators, and clinical researchers dedicated to reimagining what’s possible. We captured Dr. Suthesh Sivapalaratnam’s anticipation of this milestone just a day before the first dose in the Velora Pioneer study. The future of bleeding disorders is being written today.
